Skip to main content

Postoperative Residual Curarisation

0
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
neuromuscular transmission monitoringN/A
MSD
MSDIreland - Ballydine
1 program
neuromuscular transmission monitoringN/A1 trial
Active Trials
NCT01362647Completed625Est. Oct 2011
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
neuromuscular transmission monitoringN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDneuromuscular transmission monitoring

Clinical Trials (1)

Total enrollment: 625 patients across 1 trials

NCT01362647MSDneuromuscular transmission monitoring

Postoperative Residual Curarisation at Arrival in the Post-anesthesia Care Unit

Start: May 2011Est. completion: Oct 2011625 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.